Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
A phase 3 trial of Topotecan in small-cell lung cancer, run by Luye Pharma Group Ltd., now recruiting.
Overview
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06128837 by Luye Pharma Group Ltd., with 686 participants planned, started 2024-03-03 and due to reach its primary completion in 2028-06. Interventions recorded: Irinotecan hydrochloride liposome Injection, Topotecan. Conditions listed: Relapsed Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Shares Luye Pharma Group, Topotecan, Small-cell lung cancer.
- TrialPharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Shares Topotecan, Small-cell lung cancer.
- TrialA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Shares Topotecan, Small-cell lung cancer.
- TrialATLANTIS
Shares Topotecan, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Shares Topotecan, Small-cell lung cancer.
- TrialSafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Shares Topotecan, Small-cell lung cancer.
- TrialIDeate-Lung02
Shares Topotecan, Small-cell lung cancer.
- TargetTopoisomerase I (TOP1)
Shares Topotecan, Small-cell lung cancer.